Ten older patients with advanced osteoporosis experienced a 94 percent drop in fragility fractures following a single intravenous infusion of chemically modified autologous stem cells, according to a study published in the journal Cell and covered by Science Alert.
The intervention targeted women over 50 years old suffering from advanced bone density loss. Over the two-year post-treatment window, clinical evaluations recorded that painful bone micro-fractures dropped from 16 total events prior to treatment to just one occurrence.
Researchers at the University of Murcia extracted mesenchymal stem cells, known as MSCs, directly from the bone marrow of study participants. These precursor cells hold the biological capacity to differentiate into osteoblasts, the specialized cells responsible for synthesizing bone matrix and mineralization.
To improve homing efficiency, laboratory technicians altered the surface of the stem cells by attaching specific carbohydrate structures. Standard intravenous delivery often results in cells becoming trapped in pulmonary microcapillaries due to their physical size, which typically measures 20 to 30 micrometers in diameter.
The carbohydrate tagging aims to increase receptor binding affinity within bone marrow blood vessels. Four-month post-treatment bone biopsies demonstrated a 70 percent average increase in bone tissue area alongside improved bone density metrics.
Individuals currently managing osteoporosis should maintain standard pharmacological treatments prescribed by their physician. Anyone experiencing sudden, severe bone pain, acute loss of height, or spinal deformation must seek immediate medical evaluation rather than relying on emerging cellular therapies.
The absence of a control arm leaves open questions regarding whether concurrent osteoporosis medications influenced the outcomes. The Spanish research team also did not track cell flow after infusion, meaning direct proof of homing into human bone marrow is unconfirmed.
Robert Sackstein, a co-author of the published research, holds the intellectual property rights for the underlying cellular engineering technique. The University of Murcia is currently organizing a larger randomized controlled trial comparing autologous modified cells, donor-derived modified cells, and a group that does not receive stem cell treatment.
- Cell Journal – Experimental Autologous Mesenchymal Stem Cell Infusions in Advanced Osteoporosis
- Science Alert – Stem Cell Glycosylation and Targeted Bone Marrow Homing Trials